The increased use of psychiatric services in the US pediatric population raises concerns about the appropriate use of psychotropic medications for very young children.
T he increase in the prevalence of treated psychiatric diagnoses and the use of psychotropic medications in pediatric populations in the United States [1] [2] [3] [4] [5] has generated public health concerns, [6] [7] [8] particularly regarding the expanded use of antipsychotics for the behavioral management of children. 9 Most pediatric psychotropic medication use (67%) 10 is not approved by the US Food and Drug Administration and is therefore prescribed off-label, whereby the evidence for the benefits is not available to balance the risk of potential harm. [10] [11] [12] The differential use of psychotropic medications among poor, near-poor, and foster care children, who are more likely than privately insured youth to receive psychotropic medications, 13-15 raises social and ethical concerns. Although there is evidence to support the efficacy of stimulants in the management of attention-deficit/ hyperactivity disorder (ADHD) 16 and antipsychotics for aggression in autism spectrum disorders (ASD), 17 concerns continue unabated about off-label use and the short-and longterm neurobiological effects of early exposure to complex combinations of medications in community populations.
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During the past 20 years, cross-sectional studies have assessed the trends in psychiatric diagnosis and treatment in pediatric populations. [20] [21] [22] [23] [24] [25] However, little is known about the longitudinal patterns of pediatric use of psychiatric services. 26, 27 To our knowledge, there has been no assessment of the cumulative use of mental health services from birth in a Medicaid-insured cohort. In addition, although there is evidence to support sex differences in the prevalence of psychiatric diagnosis and treatment, 3 ,28,29 sex differences in the patterns of initiation of psychiatric services among children are largely unknown. Furthermore, little research has been devoted to developmental psychopharmacology despite concerns that early exposure to such medications in utero or in the preschool years could potentially alter physical, cognitive, and emotional development. [30] [31] [32] [33] This knowledge gap and the controversies surrounding the safety of pediatric psychotropic medication use highlight the need to understand the extent of pediatric mental health services in a longitudinal framework.
We assessed the cumulative incidence of a first psychiatric diagnosis and first use of psychotropic medication class use in a Medicaid-insured population of the same children across 8 years. To appreciate the context of service use, we assessed the cumulative incidence of psychosocial service use and the duration of psychotropic class use among medication users.
Methods

Study Design
The cohort was selected from computerized Medicaid claims data for newborns in a mid-Atlantic state in 2007 (eFigure in the Supplement) and followed up for 96 months or less through December 31, 2014. Enrollees included in the birth cohort had an enrollment record within 3 months of birth and 6 months or more of contiguous enrollment. Enrollees were lost to follow-up if they were missing 6 or more contiguous months. This study was reviewed and approved by the University of Maryland, Baltimore, institutional review board. Because deidentified, secondary administrative claims data were used, parental consent or waiver was not required.
We linked enrollment files to outpatient and physician files and dispensed prescription drug files to assess International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes, procedure codes, and date of service. The prescription drug files comprise prescription drug names and dispensing dates.
Outcome Measures
The outcome measures were the cumulative incidence of psychiatric diagnoses and psychotropic medication class use, both total and by enrollee characteristics; the cumulative incidence of the use of psychosocial services; and the annual duration of psychotropic medication class use (ages, 3-7 years). In addition, we assessed sex-specific differences in incident psychiatric diagnosis and psychotropic medication class use.
Psychiatric Diagnoses
Using ICD-9-CM codes, we identified the annual cumulative percentage of children who received a clinician-reported diagnosis from birth through age 7 years, in total and stratified by race/ethnicity, Medicaid eligibility group, and residential locale. To improve the validity of clinician-reported diagnoses, we required 2 or more diagnosis claims on separate days.
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Eight diagnostic groups were examined in the following categories: ADHD, disruptive disorders, learning disorder (LD), adjustment disorder, anxiety disorders, depression, ASD, and other psychiatric diagnoses (eTable 1 in the Supplement).
Psychotropic Medication Classes
We assessed the annual cumulative percentage of first psychotropic medication dispensing from birth through age 7 years, in total and stratified by race/ethnicity, Medicaid eligibility, and residential locale. Medications were grouped into 6 classes: stimulants, α-agonists, antidepressants, antipsychotics, anxiolytic and hypnotics, and other (ie, atomoxetine hydrochloride and anticonvulsant-mood stabilizers). Enrollees with ICD-9-CM codes for seizure disorder were excluded if they had no codes for psychiatric or developmental disorder diagnoses. Among medication users, we defined concomitant regimens as 2 or 3 or more concurrent dispensings from different medication classes for 60 days or more.
Additional Outcomes
Using Current Procedural Terminology codes, we assessed the annual cumulative percentage of the cohort who received a psychosocial service (ie, individual, family, or group psychotherapy). Medication use was minimal by age 2 years. Consequently, we estimated the annual duration of use among continuously enrolled children 3 to 7 years of age (n = 15 207). Finally, across 8 years, we assessed the distribution of any psychiatric diagnosis among medication users according to medication class.
Covariates
Study covariates included sex, race/ethnicity (white, African American, Hispanic, and other or missing), enrollees' residential locale (urban, suburban, or rural county) and 
Statistical Analysis
Using survival analysis, we estimated the 8-year cumulative incidence of psychiatric diagnosis and psychotropic medication class use, total and by covariates. In addition, we estimated the sex-specific incidence of first psychiatric diagnosis and first psychotropic medication class use. We used Kaplan-Meier estimators to address loss to follow-up owing to administrative censoring. For each 1-year interval, we calculated the cumulative incidence as the number of children with the event of interest divided by the number of children at risk. Children who were lost to administrative censoring were not counted as at risk. Cox proportional hazards regression models were used to assess statistical differences in the cumulative incidence of psychiatric diagnosis and psychotropic medication use while adjusting for covariates.
We estimated the cumulative incidence of the use of psychosocial services using Kaplan-Meier estimators. Among continuously enrolled children 3 to 7 years of age, we calculated annual unadjusted median number of days of psychotropic medication class use by total and for selected medication classes among medicated children. Using quantile regression models, we estimated the adjusted median number of days of medication class use according to eligibility group. Models were adjusted for study covariates. With χ 2 analyses, we compared the sex-specific proportions of incident psychiatric diagnoses and psychotropic medication class across 8 years. Statistical analyses were performed with SAS, version 9.4 (SAS Institute Inc), and statistical graphics were plotted with R, version 3.4.2 (R Foundation for Statistical Computing). P < .05 (2-sided) was considered significant. Figure 3 presents sex-specific data on first use of a psychotropic medication. Boys were more likely than girls to initiate psychotropic treatment with stimulants (70.1% [1059 of 1510] vs 56.4% [387 of 686]; P < .001), whereas girls were twice as likely as boys to initiate treatment with anxiolytics and hypnotics (25.2% [173 of 686] vs 13.2% [199 of 1510]; P < .001). This finding is particularly concerning because there is insufficient evidence to support the use of anxiolytics and hypnotics as first-line treatment for pediatric mental health conditions. 35 In addition, 11.5% of children who initiated treatment with psychotropic medication received chloral hydrate, 2.2% received a nonbenzodiazepine medication, and 86% received a benzodiazepine, a highly potent subclass of anxiolytics with a high potential for addiction and dependence in both pediatric and adult populations.
Results
Birth Cohort Characteristics
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By age 8 years, 1763 of 2196 children (80.5%) using psychotropic medication had received monotherapy, whereas concomitant psychotropic use for 60 days or more (range, 78-180 days) was observed among 343 of 2196 children (16.4%; percentage adjusted for right censoring) with 2 concurrent psychotropic classes and 90 of 2196 children (4.3%; percentage adjusted for right censoring) with 3 or more concurrent psychotropic classes ( Figure 1D-F) . The concurrent use of 3 or more medications was 3 to 4 times more common among children receiving foster care (11.6%; HR, 4.26; 95% CI, 2.29-7.89) and those eligible for SSI (18.4%; HR, 6.37; 95% CI, 4.01-10.13) than among income-eligible children (3.6%) (eTable 9 in the Supplement).
Other Outcomes Use of Psychosocial Services
The cumulative incidence of use of psychosocial services reached 12.2% (2612 of 35244 [percentage adjusted for right censoring]) by age 8 years; these services were predominantly family therapy while there is clinical evidence to support the use of antipsychotics for children with schizophrenia and bipolar disorder and for some children with ASD, only 15.1% of children (24 of 159) in the birth cohort using antipsychotics had a diagnosis of ASD, 1.9% (3 of 159) had a diagnosis of schizophrenia, and 6.3% (10 of 159) had a diagnosis of bipolar disorder (eTable 11 in the Supplement). This finding suggests that antipsychotics are largely used for off-label behavioral management in the birth cohort, highlighting the need for a delicate benefit-risk balance. Overall, given the considerable incidence of trauma and physical abuse among very young Medicaid enrollees, 44 the expanded use of psychotropic medications in this birth cohort is not surprising. Our cumulative estimates highlight the extent of early exposure to psychotropic medication and support the need for drug safety monitoring and outcomes research to provide evidence for the benefit-risk balance, particularly in the early years of life.
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Concomitant Medication Use
Cumulatively, 19.7% of our birth cohort (433 of 2196) received 2 or more psychotropic medications concomitantly for 60 days or more, with most concomitant use beginning after 5 years of age. Our estimate of concomitant medication use is conservative, requiring 60 or more days of overlap. Among children using 2 concomitant medications, the leading pair included stimulants and α-agonists, commonly used for behavioral management. 43 
Limitations and Strengths
Several limitations of our study should be noted. First, this study uses Medicaid data from a mid-Atlantic state and may not generalize to other Medicaid populations or privately insured populations. Second, we analyzed clinician-reported diagnoses that are less reliable than research-identified diagnoses. However, to improve validity, each diagnosis was confirmed by more than 1 claim on different days. 34 Third, we captured dispensed medications and not medication consumption. Fourth, while a comparison of multiple cohorts from overlapping years could reveal temporal changes in use patterns, we assessed a single cohort across 8 years because the literature suggests minimal temporal changes in the study population and age range across 8 years. 50 Finally, in the absence of data on death or migration, we could not account for loss to follow-up. However, more than half of the cohort was insured by Medicaid across 8 years. Much greater population retention is recorded in previous community-based cohort studies that have contributed to our understanding of early-onset psychiatric disorders.
31,51-53 In recent times, claims data have been enhanced with clinical research by Barbaresi and colleagues 38,54-56 for longitudinal studies. Our contribution is more modest because we captured services in a single-state Medicaid population without critically important data on clinical outcomes or academic performance. Nevertheless, an important strength of this longitudinal study is that it provides an 8-year cumulative incidence and duration of psychiatric service use in the same children and captures long-term exposures to medications prescribed largely off-label.
Conclusions
Early exposure to psychotropic medications and prolonged duration of use have implications for long-term safety. The data highlight the need for safety and outcomes research, particularly for health outcomes such as metabolic imbalance, weight gain, and sleep disturbances after initiation of psychotropic medication for very young children. Effectiveness research in observational cohorts should include functional improvements (eg, school performance and social relationships). The role of including parent training for medication monitoring is critical. 
